Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-12-2001 | Paper Report

Tamoxifen, angiogenesis, oestrogens and animal models

Author: Valerie Speirs

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

Angiogenesis is the remodelling of existing vasculature either by formation of new blood vessels or regression of superfluous vessels. In normal adults there is relatively little angiogenesis, but it is well documented that neovascularisation is required for tumour growth beyond a critical size. The (ER) antagonist TAM is currently the first line therapy for treatment of hormone sensitive breast cancer. However, besides its anti-oestrogenic effects, TAM has also been shown to have anti-angiogenic properties. Although there has been much work on the former, the anti-angiogenic actions of TAM are not well understood. …
Literature
1.
Blackwell KL, Haroon ZA, Shan S, Saito W, Broadwater G, Greenberg CS, Dewhirst MW: Tamoxifen inhibits angiogenesis in oestrogen receptor-negative animal models. Clin Cancer Res. 2001, 6: 4359-4364.
Metadata
Title
Tamoxifen, angiogenesis, oestrogens and animal models
Author
Valerie Speirs
Publication date
01-12-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2001-66721

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Paper Report

Phase III trial of chemotherapy ? HerceptinR in metastatic breast cancer

Review

Imaging biochemistry: applications to breast cancer

Commentary

BRCA1 function in T lymphocytes: a cellular specificity of a different kind

Review

Breast imaging technology Application of magnetic resonance imaging to early detection of breast cancer

Paper Report

Membrane oestrogen receptor

Paper Report

Normal mammary epithelial cells escape of senescence
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits